Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
For the first time, physicians can now prescribe medications that directly address the underlying cause of Alzheimer’s disease rather than merely managing symptoms. Leqembi and Kisunla represent a fundamental shift in how we treat this devastating illness—both are FDA-approved to slow cognitive decline in early-stage patients by targeting amyloid plaques, the toxic protein clumps that damage brain cells. A patient diagnosed with mild cognitive impairment or mild dementia caused by Alzheimer’s pathology now has access to disease-modifying therapy, a category of treatment that was simply unavailable five years ago. The significance of this transformation cannot be overstated.
For decades, Alzheimer’s treatment meant managing symptoms—helping patients remember to take medication, managing behavioral changes, or treating depression and anxiety. Now, a newly diagnosed patient can receive Leqembi as an at-home injectable, eliminating the burden of traveling to a clinic for intravenous infusions. This shift reflects a broader wave of discoveries that have fundamentally changed our understanding of how Alzheimer’s develops and how we can intervene before irreversible brain damage occurs. Beyond the approved medications, researchers have identified entirely new molecular targets and treatment pathways that are moving rapidly through clinical trials. These discoveries suggest that the treatment landscape for Alzheimer’s will continue to expand, offering hope to patients and families facing a diagnosis that has long carried a sense of inevitability.
Table of Contents
- What Are the Newly FDA-Approved Treatments and How Do They Work?
- Understanding the Molecular Mechanisms Behind the Breakthroughs
- Experimental Treatments Showing Remarkable Promise in Animal Research
- How Modern Alzheimer’s Treatments Compare to Yesterday’s Approaches
- What Patients and Families Should Know About Timing and Treatment Limitations
- The Critical Role of Early Detection and Diagnosis
- The Future of Alzheimer’s Treatment—What’s in the Pipeline
- Conclusion
What Are the Newly FDA-Approved Treatments and How Do They Work?
Leqembi and Kisunla are monoclonal antibodies designed to bind to amyloid plaques in the brain and help clear them. The recent mechanistic research has revealed exactly how Leqembi accomplishes this: it works by activating the brain’s immune cells, called microglia, through a specific part of the antibody known as the Fc fragment. These immune cells then engulf and remove the harmful plaques, helping restore communication between neurons and slowing the progression of cognitive decline.
The approval of Leqembi’s at-home injectable form is a practical breakthrough. Previously, patients needed to receive the medication through intravenous infusions at specialized clinics, which required trained staff, regular travel, and long infusion sessions. Now, patients can self-administer injections at home, reducing burden on caregivers and making the treatment accessible to people in rural areas or those with transportation limitations. However, it’s important to note that these medications work best when administered early—patients need to have mild cognitive impairment or mild dementia stage disease, not advanced stages where brain damage is already severe.
Understanding the Molecular Mechanisms Behind the Breakthroughs
Recent research has identified several key molecular pathways that malfunction in Alzheimer’s disease, and targeting these pathways is opening new treatment doors. In February 2026, researchers at Indiana University School of Medicine discovered that removing the IDOL enzyme from neurons substantially reduces the buildup of amyloid plaques while simultaneously improving communication between brain cells and restoring proper lipid metabolism—the process by which the brain maintains its cellular membranes. Another remarkable discovery involves two somatostatin receptors, called SST1 and SST4, that work together to regulate an enzyme called neprilysin, which naturally clears amyloid from the brain. When researchers stimulated these receptors in mouse models of Alzheimer’s, neprilysin levels increased, leading to improved amyloid clearance and measurably better memory-related behavior.
This finding suggests that activating these receptors could become a future treatment strategy, though human trials are still in early stages. Equally significant was the identification of what researchers call a “death switch”—a harmful protein interaction that causes brain cells to die and directly drives cognitive decline. Understanding this mechanism offers a new target for therapeutic intervention. The limitation here is that these discoveries, while scientifically elegant, still require years of testing before they translate into treatments available to patients. What works in a mouse brain does not automatically work in the human brain, and safety considerations must be thoroughly evaluated.
Experimental Treatments Showing Remarkable Promise in Animal Research
One of the most exciting developments involves restoring NAD+ balance in the brain. NAD+ is a critical molecule involved in cellular energy production. A groundbreaking study from Case Western Reserve University found that maintaining proper NAD+ levels not only prevented Alzheimer’s-like disease in mice but could actually reverse it, even in advanced disease stages. This is significant because previous research focused on prevention and slowing decline—not reversal. The mice that received delayed treatment, meaning treatment started after cognitive problems had already developed, achieved full neurological recovery in testing.
Lithium orotate, a novel form of the element lithium, has also demonstrated potential in preclinical models. Unlike lithium carbonate, which is used psychiatrically and can have significant side effects, lithium orotate showed promise in preventing and reversing Alzheimer’s pathology and memory loss in mouse models. However, these remain laboratory findings; lithium compounds have not yet advanced to human clinical trials for Alzheimer’s, and their safety and efficacy in people remain unknown. The challenge with experimental treatments is that we cannot yet know which ones will prove safe and effective in humans. Some animal research findings do not translate to humans, and unexpected side effects or safety concerns can halt promising research. Patients and families hoping for these emerging treatments should maintain realistic expectations while staying informed about clinical trials that may become available.
How Modern Alzheimer’s Treatments Compare to Yesterday’s Approaches
The medications available today represent a complete departure from the symptom-management era. For twenty years, the standard Alzheimer’s medications—donepezil, rivastigmine, and memantine—worked only on symptoms. They didn’t slow disease progression; they simply made existing cognitive abilities slightly more accessible. A patient taking these drugs might maintain their current level of functioning for a few additional months, but the underlying disease marched forward unchanged. Leqembi and Kisunla work differently. By attacking the underlying pathology, they can actually slow the rate at which cognitive decline occurs.
Clinical trial data showed that Leqembi slowed cognitive decline by 35 percent over 18 months in early-stage patients. While this is not a cure, and patients still experience decline, the trajectory is measurably different. A patient might maintain their independence and quality of life for months or years longer than they would without treatment. The tradeoff is that these new medications require early diagnosis and early intervention. They cannot help patients in advanced stages of dementia where the damage is already severe. They also require careful monitoring—Leqembi and Kisunla can cause AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA), which means inflammation or microhemorrhages in the brain. This is why patients receiving these treatments need regular MRI monitoring and close clinical follow-up, making them more demanding than previous symptom-management approaches.
What Patients and Families Should Know About Timing and Treatment Limitations
The window for treating Alzheimer’s with current medications is narrowing—in the sense that the earlier a patient begins treatment, the better the outcomes. This creates an urgent need for early detection. Patients often don’t recognize mild cognitive impairment until they or their families notice memory lapses or difficulty managing finances and scheduling. By the time diagnosis occurs, some irreversible damage may already have happened. Biomarker testing can now identify Alzheimer’s pathology before symptoms appear. Some patients with positive amyloid and tau biomarkers but no cognitive symptoms are already being monitored, and future clinical trials may offer preventive treatment to this group.
However, widespread biomarker screening is not yet standard practice, and access remains limited. This means many patients are diagnosed too late to benefit from the disease-modifying medications currently available. Another important limitation: these treatments do not work for all patients. Some patients with early-stage Alzheimer’s disease do not tolerate the medications well, and others do not respond adequately. Additionally, patients with genetic forms of Alzheimer’s, vascular dementia, or Lewy body dementia—different types of dementia with different underlying causes—cannot benefit from amyloid-targeting drugs. Proper diagnosis of the type of dementia is therefore essential before beginning treatment.
The Critical Role of Early Detection and Diagnosis
Early detection has become the linchpin of Alzheimer’s treatment success. Advances in biomarker testing now make it possible to identify amyloid and tau pathology through blood tests and advanced imaging before symptoms become obvious. Some experts now recommend that cognitively normal older adults with a family history of Alzheimer’s or those showing subtle changes in memory or thinking consider biomarker evaluation.
General practitioners and primary care providers are being trained to recognize mild cognitive impairment and refer patients for specialized evaluation. If you notice that a parent is struggling with names they once knew easily, cannot manage their medications without reminders, or seems to get lost driving familiar routes, these are signs that warrant evaluation by a neurologist or geriatric specialist. Early evaluation can mean the difference between accessing disease-modifying therapy and missing that window entirely.
The Future of Alzheimer’s Treatment—What’s in the Pipeline
The clinical pipeline is robust with promising candidates. Trontinemab, a next-generation amyloid-targeting drug, recently advanced to Phase III clinical trials. Anavex Life Sciences presented trial data for Blarcamesine (AD-004) at the AD/PD 2026 Conference, showing a correlation between treatment effect and brain volume preservation in early Alzheimer’s patients—suggesting it may slow the actual shrinkage of the brain that occurs with cognitive decline.
The convergence of multiple treatment pathways—amyloid targeting, tau targeting, neuroinflammation reduction, and metabolic restoration—suggests that future treatment may involve combination therapy rather than single drugs. Just as cancer treatment has evolved toward targeted combination regimens, Alzheimer’s treatment may eventually involve personalized combinations based on an individual patient’s biomarker profile. These advances highlight the remarkable progress in understanding and treating the disease, though continued research and clinical trials remain essential.
Conclusion
The discovery of multiple new treatment pathways for Alzheimer’s disease marks a turning point in neurology. For the first time, physicians can offer patients disease-modifying therapy that directly addresses the pathological changes driving cognitive decline. Leqembi and Kisunla are already in use, with additional treatment options advancing through clinical trials. Experimental approaches targeting NAD+ balance, somatostatin receptors, and other molecular pathways offer hope that the toolkit for treating Alzheimer’s will continue to expand.
The practical implications are clear: if you or a family member receives a diagnosis of Alzheimer’s disease or mild cognitive impairment, seeking evaluation at a specialized dementia center can determine whether these new treatments are appropriate. Early detection and prompt treatment initiation offer the best chance of slowing decline and preserving quality of life. While these medications are not cures and carry important limitations, they represent genuine progress in a disease that has long seemed inevitable and unstoppable. This is no longer an era where patients can only expect decline—it is an era of active, science-based intervention.
